Alkermes plc. ($ALKS)
Filing Information
| Accession Number | 0001520262-26-000058 |
|---|---|
| Form Type | 4 |
| Filing Date | Mar 4, 2026 |
| Document | View SEC Filing |
Transactions
5
Total Shares
140,605
Total Value
$364,185.40
P&L
+inf% (+$4,262,255.25)
Transactions
| Name | Title | Security | Derivative | Transaction Date | Type | Shares | Price | Total Cost | Shares After | Direct/Indirect | Nature of Ownership | Actions |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
EVP R&D, Chief Medical Officer | Ordinary Shares | โ | Mar 2, 2026 | Exercise/Conversion | 5,000 | $19.34 | $96,700.00 | 98,389 | Direct | โ | View Details | |
EVP R&D, Chief Medical Officer | Ordinary Shares | โ | Mar 2, 2026 | Sale | 9,000 | $29.72 | $267,485.40 | 89,389 | Direct | โ | View Details | |
EVP R&D, Chief Medical Officer | Employee Stock Option (Right to Buy) | Derivative | Mar 2, 2026 | Exercise/Conversion | 5,000 | $0.00 | $0.00 | 21,356 | Direct | โ | View Details | |
EVP R&D, Chief Medical Officer | Employee Stock Option (Right to Buy) | Derivative | Mar 2, 2026 | Grant/Award | 83,037 | $0.00 | $0.00 | 83,037 | Direct | โ | View Details | |
EVP R&D, Chief Medical Officer | Restricted Stock Unit Award | Derivative | Mar 2, 2026 | Grant/Award | 38,568 | $0.00 | $0.00 | 38,568 | Direct | โ | View Details |